Interchangeability of a hepatitis A vaccine second dose: Avaxim 80 following a first dose of Vaqta 25 or Havrix 720 in children in Turkey

Soysal, Ahmet; Gökçe, İbrahim; Pehlivan, Tamer; Bakır, Mustafa

doi:10.1007/s00431-007-0432-0

Cited by 10 publications

(19 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A large number of studies have been reported mainly from Turkey and Iran. The overall prevalence rate reported in different provinces of Turkey during the past 10 years among young adults (≤19 years old) ranges between 13% and 64% . An increasing trend was observed till 2008 (29% up to 63.8%) followed by a sharp decline observed in 2010 and 2012 (13% and 29.5%, respectively).…”

Section: Resultsmentioning

confidence: 98%

Hepatitis A virus in the Middle East and North Africa region: a new challenge

Melhem

Talhouk

Rachidi

et al. 2014

Journal of Viral Hepatitis

View full text Add to dashboard Cite

During the past three decades, a gradual shift in the age of infection with hepatitis A virus (HAV) from early childhood to adulthood has been observed. There is a general lack of updated data on HAV burden of disease, incidence and age-specific seroprevalence in countries of the Middle East and North Africa (MENA) region. The aim of this article is to review the published data on anti-HAV seroprevalence, an important tool to monitor infections rates, in countries of the MENA region and associated risk factors including water and socioeconomic data when available. Data on anti-HAV seroprevalence were found for 12 of 25 MENA countries. We show that MENA countries, similar to other areas in the world, have a clear shift in HAV incidence with a decline among young age groups and an increase among adults and older individuals. This would likely be associated with increased morbidity and increased risks of outbreaks among younger age groups. Consequently, the continuous surveillance of hepatitis A cases and the inclusion of hepatitis A vaccine in the expanded immunization programmes are needed in countries of the MENA.

show abstract

Section: Resultsmentioning

confidence: 98%

Hepatitis A virus in the Middle East and North Africa region: a new challenge

Melhem

Talhouk

Rachidi

et al. 2014

Journal of Viral Hepatitis

View full text Add to dashboard Cite

show abstract

“…Soysal et al did not report the reactogenicity profile of Avaxim 80U specifically but across all three childhood hepatitis A vaccines they assessed (Avaxim 80U, Havrix 720 and Vaqta 25). No immediate reactions were reported, and the rates of local and systemic solicited reactions did not differ between the three vaccines assessed after the first or the second vaccine injection [48]. The most commonly reported adverse event was pain (11.5% of participants).…”

Section: Safety Profile From Pooled Clinical Studies and Literature Rmentioning

confidence: 96%

“…The literature search identified 11 [39,40,[42][43][44][45][46][47][48][49][50] reports for inclusion in this review ( Figure S1). Although one article by Fisenka et al should have been excluded from this review because it assessed the use of three hepatitis A vaccines (i.e.…”

Section: Literature Identifiedmentioning

confidence: 99%

“…Table S3 summarizes the information collated from identified reports that forms the basis of the narrative systematic review. Of these, 10 reports included immunogenicity [39,40,[42][43][44][45][46][47][48][49] and four also reported safety data [42,45,48,49]. Overall, seven reports were from children in the indicated age group (12 months to 15 years) [39,40,42,43,[46][47][48], two were from infants aged <1 year [44,45] and one was from older children and adolescents aged 13-19 years [49].…”

Section: Literature Identifiedmentioning

confidence: 99%

“…From the literature review, we identified four studies that reported safety data [42,45,48,49]. No serious adverse events related to the pediatric HAV vaccine occurred during any of these studies.…”

Section: Safety Profile From Pooled Clinical Studies and Literature Rmentioning

confidence: 99%

See 2 more Smart Citations

Clinical experience with the inactivated hepatitis A vaccine, Avaxim 80U Pediatric

Bravo

Mege

Vigne

et al. 2019

Expert Review of Vaccines

View full text Add to dashboard Cite

Introduction: Hepatitis A, caused by hepatitis A virus (HAV), is primarily transmitted via the fecal/oral route either through ingestion of contaminated food and water or through direct contact with an infectious person. Prevalence of hepatitis A is strongly correlated with socioeconomic factors, decreasing with increased socioeconomic development, access to clean water and sanitation. Vaccination against HAV should be part of a comprehensive plan for the prevention and control of viral hepatitis, either as part of regular childhood immunization programs or with other recommended vaccines for travelers. Areas covered: We present here evidence for the immunogenicity and safety of an inactivated HAV pediatric vaccine (Avaxim® 80U Pediatric, Sanofi Pasteur), indicated for use in children aged 12 months to 15 years. Data evaluated are from trials undertaken during the clinical development of this vaccine, a systematic literature review and post-market pharmacovigilance. Expert opinion: The pediatric HAV vaccine is highly immunogenic and generates long-lasting protection against hepatitis A disease in children. The safety and immunogenicity data presented in this review suggest that the pediatric HAV vaccine is a valuable option in the prevention of HAV infection in children in many areas of the world where the disease remains a healthcare issue.

show abstract

Hepatitis A immunisation in persons not previously exposed to hepatitis A

Irving

Holden

Yang

et al. 2012

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Follow-up: 12 to 17 months Non-serious systemic adverse events (all included studies) live attenuated HAV vaccine ICH-GCP 1997 See comment See comment Insufficient evidence *The basis for the assumed risk (eg, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio. GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. Cochrane Library Trusted evidence. Informed decisions. Better health.

show abstract

Interchangeability of a hepatitis A vaccine second dose: Avaxim 80 following a first dose of Vaqta 25 or Havrix 720 in children in Turkey

Cited by 10 publications

References 29 publications

Hepatitis A virus in the Middle East and North Africa region: a new challenge

Hepatitis A virus in the Middle East and North Africa region: a new challenge

Clinical experience with the inactivated hepatitis A vaccine, Avaxim 80U Pediatric

Hepatitis A immunisation in persons not previously exposed to hepatitis A

Contact Info

Product

Resources

About